此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

YN001治疗成人冠状动脉粥样硬化的2b期临床试验 (PURIFY-TIMI 81)

2026年11月3日 更新者:Beijing Inno Medicine Co., Ltd.

一项随机、多中心、双盲、平行、安慰剂对照的2b期临床试验,旨在评估YN001在成年冠状动脉粥样硬化患者中的疗效和安全性

This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.

研究概览

详细说明

This is a multinational, multicenter, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of intravenously administered YN001 compared with placebo in participants with coronary atherosclerosis who are receiving background therapy for CV risk factors management.

A total of 456 participants are expected to be enrolled. The study will consist of a maximum 12-week screening/Baseline period, followed by a 12-week blinded treatment period, a 30-day safety follow-up, and a long-term follow-up period through Week 96 (approximately 2 years after randomization).

研究类型

介入性

注册 (估计的)

456

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • An
      • Hefei、An、中国、230022
        • 招聘中
        • The First Affiliated Hospital of Anhui Medical Unversity
        • 接触:
          • Jianlong Wang, MD
          • 电话号码:0086-13681292304
          • 邮箱:Wjlmll@sina.com
    • Anhui
      • Hefei、Anhui、中国、230001
        • 招聘中
        • Anhui Provincial Hospital
        • 接触:
        • 首席研究员:
          • Kangyu Chen, MD
        • 副研究员:
          • Chao Gao, MD
    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100035
        • 招聘中
        • Beijing Jishuitan Hospital
        • 首席研究员:
          • Wei Liu, MD
        • 接触:
          • Qingwei Ji, MD
          • 电话号码:0086 18376642655
          • 邮箱:jqwl24@163.cou
        • 首席研究员:
          • Qingwei Ji, MD
      • Beijing、Beijing Municipality、中国、100029
        • 招聘中
        • Anzhen Hospital
        • 接触:
        • 首席研究员:
          • Yuyang Liu, MD
      • Beijing、Beijing Municipality、中国、101100
        • 尚未招聘
        • Beijing Luhe Hospital
        • 接触:
    • Fujian
      • Fuzhou、Fujian、中国、350001
        • 招聘中
        • Fujian Medical University Union Hospital
        • 接触:
        • 首席研究员:
          • Mingfang Ye, MD
        • 副研究员:
          • Zhaoyang Chen, MD
    • Gansu
      • Lanzhou、Gansu、中国、730030
        • 招聘中
        • The Second Hospital & Clinical Medical School Lanzhou University
        • 接触:
    • Guangdong
      • Guangzhou、Guangdong、中国、510080
    • Heilongjiang
      • Daqing、Heilongjiang、中国、163316
        • 招聘中
        • Daqing People's Hospital
        • 接触:
      • Harbin、Heilongjiang、中国、150001
        • 招聘中
        • The First Affiliated Hospital of Harbin Medical University
        • 接触:
        • 首席研究员:
          • Lu Fu, MD
        • 首席研究员:
          • Yongtai Gong, MD
    • Hubei
      • Wuhan、Hubei、中国、430071
        • 招聘中
        • Zhongnan Hospital of Wuhan University
        • 接触:
        • 首席研究员:
          • Xiaorong Hu, MD
    • Hunan
      • Changsha、Hunan、中国、410008
        • 招聘中
        • The Second Xiangya Hospital fo Central South University
        • 接触:
    • Jilin
      • Changchun、Jilin、中国、130033
        • 招聘中
        • The First Hospital of Jilin University
        • 首席研究员:
          • Qian Tong, MD
        • 接触:
    • Liaoning
      • Shenyang、Liaoning、中国、110015
        • 招聘中
        • The People's Hospital of Liaoning Province
        • 首席研究员:
          • Ying Liu, MD
        • 接触:
    • Shaanxi
      • Xi'an、Shaanxi、中国、710068
        • 招聘中
        • Shaanxi Provincial People's Hospital
        • 接触:
    • Shandong
      • Jinan、Shandong、中国
        • 招聘中
        • Central Hospital Affiliated to Shandong First Medicial University
        • 接触:
          • Guohai Su, MD
          • 电话号码:0086 19953193319
          • 邮箱:gttstg@163.com
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200032
        • 招聘中
        • Fudan University-Zhongshan Hospital
        • 首席研究员:
          • Junbo Ge, MD
        • 接触:
        • 副研究员:
          • Yuxiang Dai, MD
      • Shanghai、Shanghai Municipality、中国、200001
        • 招聘中
        • Renji Hospital Shanghai Jiaotong University school of medicine
        • 接触:
        • 首席研究员:
          • Jun Bu, MD
    • Sichuan
      • Chengdu、Sichuan、中国、610041
        • 招聘中
        • West China Hospital of Sichuan University
        • 接触:
        • 首席研究员:
          • Yong He, MD
      • Chengdu、Sichuan、中国、610072
        • 招聘中
        • Sichuan Provincial People's Hospital
        • 接触:
    • Tianjin Municipality
      • Tianjin、Tianjin Municipality、中国、300211
        • 招聘中
        • The Second Hospital of Tianjin Medical University
        • 接触:
        • 首席研究员:
          • Tong Liu, MD
      • Tianjin、Tianjin Municipality、中国、300121
        • 招聘中
        • Tianjin People's Hospital
        • 首席研究员:
          • Zhuhua Yao, MD
        • 接触:
    • Zhejiang
      • Hangzhou、Zhejiang、中国、310006
        • 招聘中
        • Zhejiang Provincial People's Hospital
        • 接触:
      • Suzhou、Zhejiang、中国、215006
        • 招聘中
        • The First Affiliated Hospital of Soochow University
        • 接触:
      • Wenzhou、Zhejiang、中国、325000
        • 招聘中
        • The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU
        • 接触:
    • Manitoba
      • Winnipeg、Manitoba、加拿大、R2H 2A6
        • 尚未招聘
        • St. Boniface Hospital
        • 接触:
    • Ontario
      • London、Ontario、加拿大、N5A 5A5
        • 尚未招聘
        • London Health Sciences Centre
        • 接触:
      • North York、Ontario、加拿大、M6B 3H7
        • 尚未招聘
        • North York Diagnostic and Cardiac Centre
        • 接触:
      • Toronto、Ontario、加拿大、M5B 1W8
      • Vaughan、Ontario、加拿大、L6A 4N9
        • 尚未招聘
        • Cardiac Clinic
        • 接触:
    • Toronto
      • Toronto、Toronto、加拿大、M5G 2N2
        • 尚未招聘
        • Toronto General Hospital - University Health Network
        • 接触:
    • New South Wales
      • Penrith、New South Wales、澳大利亚、2750
        • 招聘中
        • Cannopy Clinical Research
        • 接触:
    • Queensland
      • Brisbane、Queensland、澳大利亚、4064
        • 招聘中
        • Core Research Group Pty Ltd.
        • 接触:
    • Victoria
      • Altona N.、Victoria、澳大利亚、3025
        • 招聘中
        • Canopy Clinical Research
        • 接触:
    • Alabama
      • Huntsville、Alabama、美国、35801-4312
        • 招聘中
        • Heart Center Research, LLC
        • 接触:
    • California
      • Covina、California、美国、91740
      • Lincoln、California、美国、95648
        • 尚未招聘
        • Clinical Trials Research
        • 接触:
      • Los Alamitos、California、美国、90720
        • 尚未招聘
        • University of California Irvine Medical Center - Cardiovascular Center
        • 接触:
      • Stanford、California、美国、94305-2200
        • 尚未招聘
        • Stanford Health Care General Cardiology
        • 接触:
      • Torrance、California、美国、90502-2006
        • 招聘中
        • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
        • 接触:
    • Florida
      • Boca Raton、Florida、美国、33434
      • Hialeah、Florida、美国、33016-1895
        • 招聘中
        • New Generation of Medical Research, LLC.
        • 接触:
      • St. Petersburg、Florida、美国、33709
    • Georgia
      • Atlanta、Georgia、美国、30303-3049
        • 尚未招聘
        • Emory Healthcare-Emory Heart & Vascular Center - Executive Park
        • 接触:
    • Idaho
      • Meridian、Idaho、美国、83642
        • 尚未招聘
        • St. Luke's Clinic - Idaho Cardiology Associates
        • 接触:
    • Illinois
      • Springfield、Illinois、美国、62781
        • 尚未招聘
        • Southern Illinois University School of Medicine
        • 接触:
    • Kansas
      • Overland Park、Kansas、美国、66211-1215
        • 招聘中
        • Midwest Heart & Vascular Specialists, LLC
        • 接触:
    • Missouri
      • St Louis、Missouri、美国、63110-1032
        • 招聘中
        • WU School of Medicine - (CAM) - Heart and Vascular Center
        • 接触:
    • North Carolina
      • Raleigh、North Carolina、美国、27607
      • Winston-Salem、North Carolina、美国、27104-3520
        • 尚未招聘
        • Javara Inc. - Wake Forest University Health Sciences
        • 接触:
    • Ohio
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73135
        • 尚未招聘
        • South Oklahoma Heart Research, LLC
        • 接触:
    • Pennsylvania
      • Camp Hill、Pennsylvania、美国、17011
        • 招聘中
        • Capital Area Research, LLC - Camp Hill
        • 接触:
    • Texas
      • Amarillo、Texas、美国、79106
        • 招聘中
        • PharmaTex Research, LLC
        • 接触:
      • Carrollton、Texas、美国、75010
        • 尚未招聘
        • Pulse Care Heart and Vascular
        • 接触:
      • Tomball、Texas、美国、77375

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Fully understands the purposes, features, and methods of the study and the possible adverse reactions, and is voluntarily willing to participate in the study, and signs the informed consent form (ICF) before performing any study-specific assessment.
  2. Male or female participants between 18 and 80 years (inclusive, at the time of signing the ICF).
  3. Participants must satisfy either of the following criteria:

1) Have clinically evident atherosclerotic CV disease (ASCVD) 2) Meet at least two of the following criteria at screening/baseline, as evidenced by:

  1. A history of Type 2 diabetes requiring treatment with medication,

  2. Aged > 55 years (women) or > 50 years (men),

  3. 2 or more of the following atherosclerosis risk factors:

    • Current cigarette smoker

    • Hypertension

    • Estimated glomerular filtration rate (eGFR) 45 to 60 ml/min/1.73m2

      4. Known coronary atherosclerosis as evidenced through coronary angiography or CCTA. The following criteria must be met on the core lab CCTA interpretation for the patient to be enrolled: at least one epicardial coronary artery with a lumen stenosis of 25% to 69%, total coronary NCPV is at least 75 mm3, Detectable low-attenuation composition in one or more individual plaques.

      5. Female participants must be non-pregnant and non-lactating

      6. Willing and able to comply with the requirements of protocol to the best of the participant's and investigator's knowledge.

Exclusion Criteria:

  1. Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.
  2. Previously received YN001.
  3. Any type of vaccination within 4 weeks prior to randomization, or any planned vaccination during the study treatment period
  4. Contraindication for CCTA
  5. 3 major epicardial coronary arteries with ≥ 70% or left main ≥50% stenosis.
  6. Acute MI that occurred within 4 weeks prior to randomization.
  7. PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.
  8. Clinically evident stroke or transient ischemic attack (TIA) within 6 months prior to randomization.
  9. Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months.
  10. Prior coronary artery bypass graft (CABG), aortic root surgery with coronary reimplantation, left ventricular assist device (LVAD) placement, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or heart transplantation, or a plan to undergo these procedures (CABG, aortic root surgery with coronary reimplantation, LVAD placement, SAVR, TAVR, or heart transplantation) during the study.
  11. New York Heart Association class III or IV or last known left ventricular ejection fraction (LVEF) was <40%.
  12. Carotid endarterectomy or stenting, peripheral arterial revascularization, or abdominal aortic aneurysm repair within 4 weeks prior to randomization.
  13. History of myopathy or myositis, or susceptibility to myopathy/rhabdomyolysis (e.g., family history of hereditary myopathy, etc.).
  14. History of severe myalgia attributed to statin therapy or other significant concern about statin side effects.
  15. Known gastrointestinal ulcers, inflammatory bowel disease, or gastrointestinal/rectal bleeding within 6 months prior to randomization.
  16. Evidence of unresolved major diseases 2 weeks prior to randomization or planned major surgery during the study that, in the investigator's judgement, may interfere with the investigational product administration or trial assessments.
  17. Presenting with history of malignancy (except in participants who have been disease-free >5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).
  18. Presence of any type of autoimmune disease.
  19. Allergy to multiple foods or drugs or known sensitivity to any components to be administered during dosing.
  20. Life expectancy is less than 1 year.
  21. Systolic blood pressure of ≥ 160 mmHg at final screening despite antihypertensive therapy.
  22. Triglycerides ≥ 400 mg/dL (4.5 mmol/L) at final screening.
  23. LDL-C > 100 mg/dL (2.6 mmol/L) at final screening.
  24. Active liver disease or hepatic dysfunction defined by any of alanine aminotransaminase (ALT), aspartate aminotransferase (AST), > 3 times upper limit of normal (ULN), or total bilirubin > 2 times ULN at final screening.
  25. Presence of renal dysfunction, defined by eGFR < 45 ml/min/1.73m2.
  26. Untreated or inadequately treated hypothyroidism.
  27. Poorly controlled Type 2 diabetes mellitus.
  28. A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).
  29. Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the participant to participate in this study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Dose 1 YN001/Placebo 40mg

Dose 1 YN001/Placobo 40mg will be administrated intravenously weekly

Dose 1 YN001/Placebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

实验性的:Dose 2 YN001/Placebo 20mg

Dose 2 YN001/Placebo 20mg will be administrated intravenously weekly

YN001/Placebo 20mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

安慰剂比较:Dose 3 YN001/Placebo 0mg

Dose 3 YN001/Placebo 0mg will be administrated intravenously weekly

YN001/Placebo 0mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Relative change from baseline in coronary NCPV at Week 13
大体时间:Baseline to Week 13

Relative change in coronary NCPV from baseline to Week 13 as determined by coronary computed tomography angiography (CCTA)

Baseline to Week 13

次要结果测量

结果测量
措施说明
大体时间
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 13
大体时间:From baseline to Week 13

Absolute change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound.

From baseline to Week 13
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9
大体时间:From baseline to Week 9

Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9

From baseline to Week 9
Relative change from baseline in carotid intima-media thickness (IMT) at Week 13
大体时间:From baseline to Week 13

Relative change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound

From baseline to Week 13
Relative change in the maximum thickness and area of carotid plaque at Week 9, and Week 13
大体时间:From baseline to Week 9 and Week 13

Relative change in the maximum thickness and area of carotid plaque from baseline to Week 9, and Week 13 as determined by carotid ultrasound

From baseline to Week 9 and Week 13
Relative change in coronary Percent Atheroma Volume (PAV) at Week 13
大体时间:From baseline to Week 13

Relative change in coronary Percent Atheroma Volume (PAV) from baseline to Week 13 as determined by CCTA

From baseline to Week 13
Relative change in coronary Low Attenuation Plaque Volume(LAPV) at Week 13
大体时间:From baseline to week 13

Relative change in coronary LAPV from baseline to Week 13 as determined by CCTA.

From baseline to week 13
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline at 48 week
大体时间:From baseline to week 48

Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline to Week 48 as determined by CCTA

From baseline to week 48
Absolute change in coronary NCPV at week 13 and week 48
大体时间:From baseline to week 13 and week 48

Absolute change in coronary NCPV from baseline to Week 13 and Week 48 as determined by CCTA

From baseline to week 13 and week 48
Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)
大体时间:From randomization to Week 96

Time to the first occurrence of the MACE, composite of CV death, myocardial infarction (MI), ischemic stroke, urgent coronary revascularization, or hospitalization for unstable angina

From randomization to Week 96
The safety profile of YN001
大体时间:From baseline to Week 13

Incidence of treatment emergent adverse event (TEAE)/serious adverse event (SAE)/adverse event of special interest (AESI)

From baseline to Week 13
Immunogenicity (ADA) analysis
大体时间:From baseline to Week 13

Incidence of anti-drug antibodies (ADA) formation

From baseline to Week 13
Immunogenicity (APA) analysis
大体时间:From baseline to Week 17

Incidence of anti-PEG antibodies (APA) formation

From baseline to Week 17
YN001 concentrations analysis in plasma
大体时间:From baseline to Week 13

Sparse blood samples will be collected, and these concentrations are intended to be pooled with other studies to develop/update pharmacometric models

From baseline to Week 13

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Ying Chen, PhD、Beijing Inno Medicine Co., Ltd.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年7月31日

初级完成 (估计的)

2027年7月31日

研究完成 (估计的)

2029年3月31日

研究注册日期

首次提交

2026年4月2日

首先提交符合 QC 标准的

2026年4月2日

首次发布 (实际的)

2026年4月9日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • YN001-203
  • IND 157167 (注册表标识符:Beijing Inno Medicine Co., Ltd.)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅